share_log

Revance Therapeutics | 8-K: Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

SEC ·  May 10 04:16
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.